Table 1.
Characteristic | Group A (midazolam + denosumab*) (N = 19) | Group B (Midazolam Alone†) (N = 8) |
---|---|---|
Gender, n (%) | ||
Female | 19 (100.0) | 8 (100.0) |
Race, n (%) | ||
White | 17 (89.5) | 6 (75.0) |
Black/African American | 1 (5.3) | 1 (12.5) |
Asian | 1 (5.3) | 1 (12.5) |
Age (years) | ||
Mean (SD) | 64.4 (6.16) | 66.3 (5.34) |
Range | 55–73 | 59–75 |
≥65 years, n (%) | 12 (63.2) | 4 (50.0) |
Bone mineral density T-score, mean (SD) | ||
Total hip | −2.07 (0.68) | −2.15 (0.65) |
Lumbar spine | −2.96 (0.76) | −2.68 (0.92) |
SD, standard deviation.
Midazolam 2 mg orally on day 1 and day 16, and denosumab 60 mg subcutaneously on day 2.
Midazolam 2 mg orally on day 1 and day 16.